EW.NYSEEdwards Lifesciences CORP

10-Q: Edwards Lifesciences Reports Q1 2025 Results: TMTT and TAVR Sales Drive Growth

Sentiment:

Quarterly Report

📋All filings for Edwards Lifesciences CORP
🔒Login to Follow

Edwards Lifesciences' Q1 2025 net sales increased by 6.2% year-over-year, driven by strong performance in Transcatheter Mitral and Tricuspid Therapies (TMTT) and Transcatheter Aortic Valve Replacement (TAVR) product groups.

Summary

  • Edwards Lifesciences reported net sales of $1.41 billion for the first quarter of 2025, a 6.2% increase compared to $1.33 billion in the same period of 2024.
  • The growth was primarily driven by increased sales in the Transcatheter Mitral and Tricuspid Therapies (TMTT) and Transcatheter Aortic Valve Replacement (TAVR) product groups.
  • TAVR sales increased by 3.8% to $1.05 billion, driven by higher sales of the Edwards SAPIEN platform, particularly the SAPIEN 3 Ultra RESILIA valve.
  • TMTT sales saw a significant increase of 58.1% to $115.2 million, attributed to higher sales of the PASCAL system and the continued launch of the EVOQUE tricuspid valve replacement system.
  • Surgical Structural Heart sales increased slightly by 0.7% to $250.9 million.
  • The company's diluted earnings per share increased, reflecting the operational performance.
  • The effective income tax rate increased to 16.2% from 12.5% due to an increase in global minimum tax and a decrease in the tax benefit from employee share-based compensation.
  • The company expects Pillar Two provisions to result in approximately $60 million in additional tax expense in 2025.
  • The company repurchased 3.4 million shares at an aggregate cost of $306.9 million, including an accelerated share repurchase agreement.
  • As of March 31, 2025, the company had $1.1 billion remaining authorized for share repurchases.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong sales growth in key product areas. However, ongoing tax disputes and increased tax expenses temper the overall sentiment.

Positives

  • Net sales increased by 6.2% year-over-year, indicating strong market demand for Edwards' products.
  • TMTT sales experienced substantial growth of 58.1%, demonstrating the success of new product launches and market penetration.
  • TAVR sales also increased, driven by the adoption of the SAPIEN 3 Ultra RESILIA valve.
  • The company has a strong cash position and available credit facilities to support future growth and strategic initiatives.
  • Share repurchases demonstrate confidence in the company's future performance and provide value to shareholders.

Negatives

  • The increase in the effective income tax rate to 16.2% may negatively impact net income.
  • The company expects Pillar Two provisions to result in approximately $60 million in additional tax expense in 2025.
  • Ongoing tax disputes with the IRS and the Israel Tax Authority could result in material financial impacts.
  • Foreign currency exchange rate fluctuations negatively impacted net sales outside of the United States by $15.1 million for the three months ended March 31, 2025.

Risks

  • Ongoing intellectual property and tax litigation could result in significant expenses and adverse outcomes.
  • Changes in tax laws and regulations, particularly the implementation of Pillar Two, could increase the company's tax burden.
  • Adverse outcomes in ongoing tax audits by the IRS and the Israel Tax Authority could materially affect the company's financial condition and results of operations.
  • The medical technology industry is highly competitive and continues to evolve.
  • The company's success is measured both by the development of innovative products and the value it brings to its stakeholders.

Future Outlook

The company expects Pillar Two provisions to result in approximately $60 million in additional tax expense in 2025. The company plans to vigorously contest the additional tax claimed by the IRS through the judicial process. Final resolution of this matter is not likely within the next 12 months.

Management Comments

  • We are committed to developing new technologies and innovations, and we are committed to defending our intellectual property in support of those developments.
  • Our vision for growth is to treat patients with both valvular and non-valvular structural heart disease, such as heart failure, which is a natural progression of the disease for many patients suffering from aortic stenosis and mitral and tricuspid regurgitation.
  • We are dedicated to generating robust clinical, economic, and quality-of-life evidence increasingly expected by patients, clinicians, and payors in the current healthcare environment, with the goal of encouraging the adoption of innovative new medical therapies that demonstrate superior outcomes.

Industry Context

Edwards Lifesciences operates in the highly competitive medical technology industry, focusing on structural heart disease. The company's growth strategy involves developing innovative products and generating clinical evidence to support their adoption. The industry is also subject to evolving healthcare regulations and reimbursement policies, which impact the adoption of new medical therapies.

Comparison to Industry Standards

  • Medtronic and Abbott are major competitors in the structural heart market.
  • Edwards' TAVR sales growth is in line with industry trends, but TMTT growth significantly outpaces competitors due to recent product launches.
  • The company's focus on clinical evidence aligns with industry standards for demonstrating the value of new medical technologies.
  • The company's tax rate is comparable to other multinational corporations in the medical device industry, but the ongoing tax disputes are a unique risk factor.

Legal Proceedings

  • Aortic Innovations LLC filed a lawsuit against Edwards Lifesciences Corporation alleging that Edwards SAPIEN 3 Ultra product infringes certain of its patents.
  • The European Commission is investigating certain business practices of Edwards, including its unilateral pro-innovation (anti-copycat) policy and patent practices.
  • Fortis Advisors, LLC, filed suit against the Company in the Court of Chancery of the State of Delaware, alleging breach of the Agreement and Plan of Merger.
  • A purported stockholder of Edwards filed a putative securities class action complaint against the Company and certain of its executive officers in the United States District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation.
  • Plaintiff Manh Ho filed a shareholder derivative action in the United States District Court for the Central District of California, captioned Ho v. Zovighian, et al.
  • Plaintiff Barbara Sheridan filed a different shareholder derivative action in the United States District Court for the Central District of California, Sheridan v. Zovighian, et al.

Stakeholder Impact

  • Shareholders will benefit from the company's strong financial performance and share repurchase program.
  • Employees will benefit from the company's growth and investment in research and development.
  • Patients will benefit from the company's innovative therapies for structural heart disease.
  • Clinicians will benefit from the company's commitment to generating clinical evidence to support the adoption of new therapies.

Next Steps

  • The company will continue to launch and expand the adoption of its TMTT products, including PASCAL and EVOQUE.
  • Edwards will continue to invest in research and development to drive innovation in structural heart disease therapies.
  • The company will vigorously defend its intellectual property and contest ongoing tax disputes.
  • Edwards will monitor and adapt to evolving healthcare regulations and reimbursement policies.

Key Dates

DateDescription
December 8, 2015Date of the Agreement and Plan of Merger between Harpoon Medical, Inc. and Edwards.
June 15, 2018Date of issuance of $600.0 million of 4.3% fixed-rate unsecured senior notes due June 15, 2028.
April 2021The Company entered into a promissory note agreement, a preferred stock purchase agreement, and an option agreement with a privately-held medical device company.
November 2022The Company made deposits with the IRS of $75 million.
February 2023The Company acquired a majority equity interest in a medical technology company pursuant to a preferred stock purchase agreement, and amended and restated a previous option agreement to acquire the remaining equity interest.
March 22, 2024Fortis Advisors, LLC, filed suit against the Company in the Court of Chancery of the State of Delaware, alleging breach of the Agreement and Plan of Merger.
March 31, 2024Financial results for the three months ended March 31, 2024.
March 31, 2024The Company made deposits with the IRS of $305.1 million.
June 3, 2024The Company entered into a definitive agreement to sell Critical Care to Becton, Dickinson and Company ('BD').
July 2024The Company entered into an agreement and plan of merger to acquire JenaValve Technology, Inc. ('JenaValve').
July 15, 2024The Company has a Five-year Credit Agreement (the 'Credit Agreement') which provides for a $750.0 million multi-currency unsecured revolving credit facility and matures on July 15, 2027.
August 2024The Board of Directors approved a stock repurchase program providing for up to $1.5 billion of repurchases of our common stock.
September 3, 2024The sale of Critical Care to Becton, Dickinson and Company ('BD') was completed.
October 14, 2024A purported stockholder of Edwards filed a putative securities class action complaint against the Company and certain of its executive officers in the United States District Court for the Central District of California, captioned Patel v. Edwards Lifesciences Corporation.
December 20, 2024The Company filed administrative claims for refunds of those payments with the IRS for the 2015 through 2017 tax years.
December 31, 2024Plaintiff Manh Ho filed a shareholder derivative action in the United States District Court for the Central District of California, captioned Ho v. Zovighian, et al.
January 17, 2025Plaintiff Barbara Sheridan filed a different shareholder derivative action in the United States District Court for the Central District of California, Sheridan v. Zovighian, et al.
January 2025The United States issued an executive order announcing opposition to aspects of these rules.
February 2025The Company entered into a $250.0 million accelerated share repurchase ('ASR') agreement and received, on February 14, 2025, an initial delivery of 2.6 million shares of our common stock, representing approximately 80 percent of the total contract value.
February 27, 2025Donald E. Bobo, Jr., Corporate Vice President, Strategy & Corporate Development, entered into a Plan providing for the potential sale of 66,650 shares of the Company's stock commencing June 2, 2025.
February 27, 2025Larry L. Wood, Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart, entered into a Plan providing for the potential sale of 53,700 shares of the Company's stock commencing May 30, 2025.
February 28, 2025Bernard J. Zovighian, Chief Executive Officer and Director, entered into a Plan providing for the sale of an estimated 62,833* shares of the Company's stock commencing May 30, 2025.
March 31, 2025Financial results for the three months ended March 31, 2025.
April 10, 2025The Court consolidated the Ho Action and the Sheridan Action (now referred to as the Consolidated Derivative Action).
April 2025The Company advanced an additional $7.5 million under the note agreement.
April 2025The Company invested an additional $1.8 million in the Investee's preferred equity securities and $4.0 million for the option to acquire the Investee.
April 2025The company received United States Food and Drug Administration ('FDA') approval for the SAPIEN 3 platform for severe aortic stenosis patients without symptoms.
April 2025The company received CE Mark for the Edwards SAPIEN M3 mitral valve replacement system for the transcatheter treatment of patients with symptomatic (moderate-to-severe or severe) mitral regurgitation who are deemed unsuitable for surgery or transcatheter edge-to-edge therapy.
July 25, 2025The ASR agreement has a scheduled termination date of July 25, 2025.
December 2025The trial for the Fortis Advisors, LLC, lawsuit is scheduled for December 2025.
June 15, 2028The cross-currency swap contracts have an expiration date of June 15, 2028.

Keywords

TAVR, TMTT, Edwards Lifesciences, Net Sales, Financial Results, Share Repurchase, Tax Litigation, SAPIEN 3, EVOQUE, PASCAL

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.